CD33-CLL1 multiplex-engineered eHSC therapy- Vor Biopharma
Alternative Names: CD33-CLL1 Treatment System - Vor BiopharmaLatest Information Update: 30 May 2024
At a glance
- Originator Vor Biopharma
- Class Antineoplastics; Gene therapies; Haematopoietic stem cells therapies; Immunotherapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute myeloid leukaemia